Jazz Pharmaceuticals JAZZ Unrecognized Tax Benefits Increases Resulting From Acquisition
Unrecognized Tax Benefits Increases Resulting From Acquisition at other companies
Other financials
Where this comes from
Reported directly by Jazz Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition.
The official record: Jazz Pharmaceuticals’s 10-K, filed February 24, 2026, on SEC EDGAR. View the filing →
Ask your AI about Jazz Pharmaceuticals's unrecognized tax benefits increases resulting from acquisition.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Jazz Pharmaceuticals's unrecognized tax benefits increases resulting from acquisition?
- Jazz Pharmaceuticals (JAZZ) reported unrecognized tax benefits increases resulting from acquisition of $4.67M in Q4 2025.
- What is the long-term trend for Jazz Pharmaceuticals's unrecognized tax benefits increases resulting from acquisition?
- Over 4 years (2021 to 2025), Jazz Pharmaceuticals's unrecognized tax benefits increases resulting from acquisition has grown at a 33.3% compound annual growth rate (CAGR), from $5.92M to $18.66M.
- What does unrecognized tax benefits increases resulting from acquisition mean?
- The amount of tax uncertainty added to the balance sheet due to an acquisition.
- How do you interpret unrecognized tax benefits increases resulting from acquisition?
- An increase indicates the acquisition of potential tax liabilities or complex tax structures that require ongoing monitoring and potential future resolution.
- How does unrecognized tax benefits increases resulting from acquisition compare across companies?
- Highly dependent on M&A activity; peers with frequent acquisitions will show higher volatility in this metric.